Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: An analysis of integrated data

Medicine & Life Sciences

• valdecoxib 100%
• parecoxib 97%
• Cyclooxygenase 2 Inhibitors 70%
• Data Analysis 44%
• Safety 34%
• Placebos 22%
• Incidence 13%
• Datasets 8%
• Cyclooxygenase Inhibitors 6%
• Prodrugs 6%
• Postoperative Pain 5%
• Pain Management 5%
• Coronary Artery Bypass 5%
• Anti-Inflammatory Agents 4%
• Cohort Studies 3%
• Transplants 3%
• Pharmaceutical Preparations 2%